A model for developing a decision support system to simulate national drug policy indicators.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Decisional conflict and vaccine uptake: cross-sectional study of 2012/2013 influenza season in Croatia.Archives of medical science : AMS · 2015
   Article
2. Consistent defined threshold and equity in health.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2015
   Article
3. A system dynamics model for national drug policy.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2014
   Article
4. A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience.Archives of medical science : AMS · 2013
   Review
5. Trend analysis of the pharmaceutical market in Iran; 1997-2010; policy implications for developing countries.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2013
   Article
6. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2013
   Article
7. Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer.Archives of medical science : AMS · 2013
   Article
8. Assessment of the vaccine industry in Iran in context of accession to WTO: a survey study.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2012
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.